Chengxu Cui

机构：Chinese Academy of Medical Sciences & Peking Union Medical College

发表论文 41 篇 · 总被引 1530 次 · h-index 13

代表论文

• Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial (2022 · Cancer Cell · 被引 578)
• Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial (2021 · Journal of Clinical Oncology · 被引 417)
• Clinical and biomarker analyses of sintilimab versus chemotherapy as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma: a randomized, open-label phase 2 study (ORIENT-2) (2022 · Nature Communications · 被引 151)
• An immunogenic and oncogenic feature-based classification for chemotherapy plus PD-1 blockade in advanced esophageal squamous cell carcinoma (2023 · Cancer Cell · 被引 53)
• Nab-paclitaxel plus S-1 as first-line followed by S-1 maintenance for advanced pancreatic adenocarcinoma: a single-arm phase II trial (2018 · Cancer Chemotherapy and Pharmacology · 被引 25)
• 1373MO JUPITER-06: A randomized, double-blind, phase III study of toripalimab versus placebo in combination with first-line chemotherapy for treatment naive advanced or metastatic esophageal squamous cell carcinoma (ESCC) (2021 · Annals of Oncology · 被引 24)